Home | About | RSS Feed | Contact and Publicity Guidelines | Comment Policy the Law, the Universe, and Everything 


advertise-here4


Slip Opinions


Most under-appreciated thing about Warren Buffett: he built Berkshire to last well beyond him.  (LAC, at BRK annual meeting via Motley Fool, here.)

University governance as a new topic of public discussion.

An unusual profile of Mary Anne Franks (kw)

Aggressive copyright litigation run amok. (fp)

USA Today's Matt Krantz quoting me on Warren Buffett joining Twitter.  (LAC)

Private prisons? Why, sure! What could possibly go wrong? (kw)

TNR profiles Susan Crawford (kw)

Berkshire Hathaway is bigger than Warren Buffett.  Manual of Ideas (LAC).

Guns don't shoot people, kitchen appliances shoot people (kw)

Via Glom, Sat Eve Post review of The Essays of Warren Buffett.


Our Podcast

Subscribe to Law Talk


  • Posts by Author

  • Categories

  • Archives


  • Recent Comments


    • Brett Bellmore on National Referenda

    • Gerard Magliocca on National Referenda

    • mls on National Referenda

    • David Schwartz on The Varying Use of Legal Scholarship by the U.S. Supreme Court across Issues

    • Patrick S. O'Donnell on Warren Buffett: Practical Philosopher of Capitalism

    • Ken Shubin Stein on Is Berkshire Hathaway Really a Psychology Experiment?

    • Patrick S. O'Donnell on Is Berkshire Hathaway Really a Psychology Experiment?

    • Ken Shubin Stein on Warren Buffett: Practical Philosopher of Capitalism

    • Ken Shubin Stein on Is Berkshire Hathaway Really a Psychology Experiment?

    • Orin Kerr on The Varying Use of Legal Scholarship by the U.S. Supreme Court across Issues

    • David Schwartz on The Varying Use of Legal Scholarship by the U.S. Supreme Court across Issues

    • Matt on Is Berkshire Hathaway Really a Psychology Experiment?

    • Orin Kerr on The Varying Use of Legal Scholarship by the U.S. Supreme Court across Issues

    • Guy Spier on Is Berkshire Hathaway Really a Psychology Experiment?

    • Griff on The Varying Use of Legal Scholarship by the U.S. Supreme Court across Issues
  •  

    Site Meter

    About the Blog

    Concurring Opinions is a multiple authored, general interest legal blog.

    (Image: Wikicommons)

Reefer Madness At The FDA

posted by Dan Filler

marijuana-leaf.jpgOne of the most troubling behaviors of the current administration is its repeated willingness to manipulate the distribution of empirical data with which it disagrees. From global warming to crime, the government seems more interested in promoting its policy preferences than transparently reporting the results of the research it performs or supports. The administration has a legitimate right to advocate for its positions. But if it wants to argue that marijuana ought to be illegal, as the FDA did last week in its Inter-Agency Advisory Regarding Claims That Smoked Marijuana Is A Medicine, it seems to me the better policy – both from an honesty and a credibility point of view – is to concede the facts that cut against you, and make your case anyway. In its press release last week, the FDA asserted that:

A past evaluation by several Department of Health and Human Services (HHS) agencies, including the Food and Drug Administration (FDA), Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute for Drug Abuse (NIDA), concluded that no sound scientific studies supported medical use of marijuana for treatment in the United States.

True as this may be, a 1999 review of studies by the National Institute of Medicine suggests that marijuana offers potential therapeutic value for pain relief, control of nausea and vomiting, and appetite stimulation. Also, it notes that “until a non-smoked, rapid-onset cannabanoid drug delivery system becomes available…there is no clear alternative” to smoking. Why can’t the administration concede the existence of this data review by another federal agency?

It seems to me that the administration is driven by a decision, ex ante, that marijuana ought to be illegal. If it were truly interested in investigating the utility of the drug, it wouldn’t make serious research into its value exceedingly difficult. So the federal government ignores data suggesting the value of marijuana. It makes it hard to generate more research on marijuana. And it is therefore able to rail against the many states that have legalized marijuana for medical purposes. There are reasons to believe that, if the government allowed the debate to flourish – by sharing data that does exist and promoting the production of new data – its position might become weaker. But if marijuana is in fact effective as a medicine, perhaps the FDA should legalize it. And if the government’s real argument is something other than efficacy – that it is very likely to be misued, for example, or that its increased availability will lead to a rise in DUI cases – then it should make that case instead.

In some respects, this approach to policy debate reminds me of an argument made by death penalty opponents who argue that the death penalty is bad policy because it is expensive. But why is it expensive? Because opponents litigate these cases very aggressively. There are many good reasons why some people may oppose the death penalty. But it seems to me that when the people complaining about the cost of capital punishment are the people generating this expense, one should at least be skeptical. I’m not denying that the expense argument might mask a a deeper claim: perhaps these cases are so expensive, and require so many appeals, because the state fails to provide excellent counsel in the first instance. But if this is true, wouldn’t a more logical solution to the cost problem be a requirement that states spend money on quality counsel up front, to save in the long haul? In the end, the real claim underneath cost is fairness: the quality of a person’s lawyer should not determine whether he receives a death sentence. That may not “sell” as well to certain voters, but it is the more honest argument.

As for reefer, when government is making the arguments, I think we have a right to expect honesty. The FDA’s dubious pronouncement appears driven primarily by the administration’s emotional hatred of marijuana. Personally, I’d prefer FDA decisions to be grounded in evidence-based research rather than simply madness.


 April 24, 2006 at 12:41 am   Posted in: Administrative Announcements, Criminal Law, Empirical Analysis of Law, Politics   Print This Post Print This Post

Responses (6)

  1. John Armstrong - April 24, 2006 at 10:53 am

    I’ve said it before and I’ll say it again: the largest ideological divide in this country is one of epistemology — between the experimentalists and the gnostics. The experimentalists believe that observed events reflect reality and construct their realities from observations, while the gnostics construct their realities from fundamental points of faith and disregard or discredit observations which disagree with those points.

    As an example, the 2004 poll showing that Kerry supporters were generally accurate about Kerry’s positions while Bush supporters were generally inaccurate about his. Some try to spin this as an indictment of Bush voters’ attention, but what I think it clearly shows is that they have started with the point “Bush (or Republican) is good”, added their intuition that “labor and environmental standards in trade agreements are good” (or the US being part of the Comprehensive Test Ban Treaty, the International Criminal Court, the treaty banning land mines, or the Kyoto Treaty on global warming; or…) and concluded that Bush was also in favor of those points, despite what observations and explicit statements show.

    In this case, the gnostics in the FDA have already taken as given that marijuana is categorically bad, and so that is the Truth to them, despite what experimental observations may or may not show. You’re trying to argue as an experimentalist that these studies have any weight at all to compare with the fundamental point of faith. You’re not going to convince anyone to change their ways, because the whole notion of epistemology underlying your well-reasoned post is flawed in their estimation.

  2. Liz L - April 24, 2006 at 11:05 am

    Professor Filler- I am glad you are addressing this issue; I wanted to discuss marijuana in the context of Profsesor Anderson’s “Drunk at Duke” posting. I would argue that marijuana is the most benign of any illegal drug, safer even (both health wise and external risk wise) than alcohol. As you point out, this Administration continuously twists data unfavorable to its Mission, thus clouding the debate on issues such as the legalization of pot. Aside from the theraputic benefits to marijuana, there are economic reasons for legalization. First, tax revenue from its legalized sale would be staggering. Second, the costs of prosecution and incarceration of pot smokers would drop. Check out “Reefer Madness” by Eric Scholosser. It’s all in there.

  3. Liz L - April 24, 2006 at 11:08 am

    That’s Eric Schlosser. I apologize.

  4. Alex Geisinger - April 24, 2006 at 11:36 am

    Dan,

    Thanks for posting on this issue. I take the earlier point on experimentalism versus gnosticism but wonder whether the timing suggests something else.

    As we gear up for another election cycle, faith-based groups are starting again to bang the drum on homosexual unions (see the April 24th edition of the New York Times reporting on 50 religious leaders signing a petition for a constitutional amendment banning same-sex marriages) and I expect legalization of marijuana may be the latest entry in the “culture” wars. Currently about 11 states allow medical use of marijuana, including California, Colorado, Nevada, Oregon and Washington. Some midwestern states (Illinois and Wisconsin) are reported to be considering laws allowing the medical use of marijuana as well. While this type of issue doesn’t necessarily resonate with social conservatives in the way that Christian issues may, it nevertheless may impact the views of many conservatives and, perhaps, even some soccer moms. In a year of potentially-close elections, mary jane may be just what the doctor ordered (for republicans, at least)!!!

  5. Maryland Conservatarian - April 24, 2006 at 3:45 pm

    “Why can’t the administration concede the existence of this data review by another federal agency?’

    well, actually that wasn’t another federal agency that did the review – yes, the study was done at the behest of the ONDCP but it was the Institute of Medicine which did the study. IOM is part of the National Academy of Sciences which isn’t a federal agency.

    That said, I agree that the federal government should allow the states to set their own policy on this issue…as well as on most matters. That’s the problem with an overarching federal government – social conservatives can co-opt it to put forth their own agenda….insert ‘petard’ comment here…

  6. gloster - July 2, 2008 at 9:23 am

    It is well known in the drug policy field that eleven states reduced the criminal sanctions associated with possession of small amounts of marijuana.

    gloster

    Addiction Recovery Colorado

    Addiction Recovery Colorado

Leave a Reply

Spam protection by WP Captcha-Free


  • « Previous post
  • Next post »

Authors

Daniel J. Solove
Kaimipono Wenger
Dave Hoffman
Frank Pasquale
Deven Desai
Danielle Citron
Lawrence Cunningham
Sarah Waldeck
Jaya Ramji-Nogales
Solangel Maldonado
Gerard Magliocca

Guests

Kelli A. Alces
Taunya Lovell Banks
Ryan Calo
Claire Hill
Jay Kesten
William McGeveran
Meredith Render
Aaron Saiger
David L. Schwartz
Olivier Sylvain
Charles K. Whitehead
Aaron Zelinsky


















Previous Guests

Michael Abramowicz
Michelle Adams
Robert Ahdieh
Marvin Ammori
Michelle Anderson
Laura Appleman
Derek Bambauer
Taunya Lovell Banks
Ann Bartow
Steven Bellovin
Adam Benforado
Gaia Bernstein
Francesca Bignami
Josh Blackman
Joseph Blocher
Jeremy Blumenthal
Kathleen Boozang
Bruce Boyden
Donald Braman
Khiara Bridges
Al Brophy
Neil H. Buchanan
Bill Burke-White
Scott Burris
Paul Butler
Ryan Calo
Naomi Cahn
Anupam Chander
Miriam Cherry
Jack Chin
Glenn Cohen
Gabriella Coleman
Jennifer Collins
Caroline Mala Corbin
Thomas Crocker
andré douglas pond cummings
Allison Danner
Laura DeNardis
Brannon Denning
Deven Desai
Mike Dimino
Mark Edwards
Maxine Eichner
Jessica Erickson
David Fagundes
Lisa Fairfax
Joshua Fairfield
Christine Haight Farley
Kim Ferzan
Dan Filler
Mary Anne Franks
Susan Freiwald
Michael Froomkin
Amanda Frost
Brian Frye
Timothy Glynn
Rachel Godsil
Eric Goldman
Kyle Graham
David Gray
Craig Green
Tristin Green
Jonathan Hafetz
Vivian E. Hamilton
Meredith Harbach
Michelle Harner
Angela Harris
Jeffrey Harrison
Hosea Harvey
Erica Hashimoto
Jennifer Hendricks
Carissa Hessick
Laura Heymann
Robert Hillman
Gilbert A. Holmes
Nicole Huberfeld
Christine Hurt
Darian Ibrahim
Sherrilyn Ifill
John Ip
Shavar Jeffries
Kevin Johnson
Kristin Johnson
Jeff Jonas
Courtney Joslin
Dan Kahan
Jeffrey Kahn
Brian Kalt
Sam Kamin
Michael Kang
Chimène Keitner
Alicia Kelly
Orin Kerr
Nancy Kim
Heidi Kitrosser
Adam Kolber
Russell Korobkin
Alex Kreit
Anita S. Krishnakumar
Susan Kuo
Greg Lastowka
Sarah Lawsky
Youngjae Lee
Margaret Lewis
Erik Lillquist
Jeff Lipshaw
Jonathan Lipson
Jacqueline Lipton
Matthew Lister
Joseph Liu
Michael Madison
Tayyab Mahmud
Kevin Noble Maillard
Solangel Maldonado
Jason Mazzone
Linda McClain
William McGeveran
Salil Mehra
Carrie Menkel-Meadow
Max Minzner
Viva Moffat
Scott Moss
Eric Muller
Janai Nelson
Jaya Ramji-Nogales
Helen Norton
Elizabeth Nowicki
Paul Ohm
Angela Onwuachi-Willing
David Opderback
David Orentlicher
Michael O'Shea
Kristen Osenga
Mary-Rose Papandrea
Rafael Pardo
Marcy Peek
Eduardo Peñalver
Robert Percival
Michael J. Pitts
Marc Poirier
David Post
Amanda Pustilnik
Shruti Rana
Geoffrey Rapp
William Reynolds
Neil Richards
Lori Ringhand
Alice Ristroph
Marc Roark
Brishen Rogers
Sasha Romanosky
Tuan Samahon
Susan Scafidi
David Schleicher
David Schraub
Paul Secunda
Lea Shaver
Jonathan Siegel
Jessica Silbey
Peter Smith
Judd Sneirson
Adam Steinman
Charles Sullivan
Rick Swedloff
Peter Swire
Olivier Sylvain
Steph Tai
Andrew Taslitz
Robert Tsai
Jenia Turner
Joseph Turow
Steve Vladeck
Ari Waldman
Spencer Weber Waller
Howard Wasserman
Melissa Waters
Elizabeth A. Wilson
Frank Wu
Alfred Yen
Corey Yung
David Zaring
Timothy Zick
Michael Zimmer
Jonathan Zittrain

Ownership

Concurring Opinions is a
general-interest legal blog
operated by Concurring
Opinions LLC, a Pennsylvania
Limited Liability Corporation.

Blogroll

Above the Law
Access to Justice
ACS Blog
Althouse
Balkinization
Becker-Posner Blog
BlackProf
BoingBoing
Chicago Law Faculty Blog
Conglomerate
CrimLaw
Crime & Federalism
CrimProf Blog
Crooked Timber
Derechoalderecho
Discourse.net
Dorf on Law
Election Law
Emergent Chaos
The Faculty Lounge
Feminist Law Profs
43(B)log
Freakonomics Blog
Freedom to Tinker
Google Blogoscoped
How Appealing
Ideoblog
Info/Law
Instapundit.com
Juris Novus
Jurisdynamics
Just Books
Law and Humanities Blog
Law and Letters
Law Librarian Blog
Legal Profession Blog
Legal Theory Blog
Legal Times Blog
Leiter Reports
Brian Leiter's Law School Reports
Lessig Blog
Madisonian Theory
Media Law Blog
Mirror of Justice
The Moderate Voice
National Security Advisors
Opinio Juris
Point of Law
PrawfsBlawg
Privacy and Security Training
ProfessorBainbridge.com
Property Prof Blog
Red Tape Chronicles
The Right Coast
Schneier on Security
SCOTUSBlog
Security Dilemmas
Sentencing Law and Policy
Simple Justice
Sivacracy.net
The Situationist
Susan Crawford
TalkLeft
Talking Points Memo
TaxProf Blog
TeachPrivacy Blog
Tech & Marketing Law
Truth on the Market
Volokh Conspiracy
WorkPlace Prof Blog
WSJ Law Blog
Wonkette
The Yin Blog


© Concurring Opinions

Powered by WordPress